Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M D Hellmann

Showing results (11-20 of 30) with videos related to

Pageof 3
Sort By:
European Journal of Cancer (Oxford, England : 1990)|April 5, 2016
Characterisation and management of dermatologic adverse events to agents targeting the PD-1 receptorV R Belum, B Benhuri, M A Postow, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|December 22, 2016
Antibody-mediated thyroid dysfunction during T-cell checkpoint blockade in patients with non-small-cell lung cancerJ C Osorio, A Ni, J E Chaft, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|April 5, 2018
Negative association of antibiotics on clinical activity of immune checkpoint inhibitors in patients with advanced renal cell and non-small-cell lung cancerL Derosa, M D Hellmann, M Spaziano, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|April 9, 2016
Clinical outcomes with pemetrexed-based systemic therapies in RET-rearranged lung cancersA Drilon, I Bergagnini, L Delasos, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|February 8, 2017
Pembrolizumab as first-line therapy for patients with PD-L1-positive advanced non-small cell lung cancer: a phase 1 trialR Hui, E B Garon, J W Goldman, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|September 6, 2021
Clinical definition of acquired resistance to immunotherapy in patients with metastatic non-small-cell lung cancerA J Schoenfeld, S J Antonia, M M Awad, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|March 18, 2020
Clinical and molecular correlates of PD-L1 expression in patients with lung adenocarcinomasA J Schoenfeld, H Rizvi, C Bandlamudi, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|May 9, 2022
Deciphering radiological stable disease to immune checkpoint inhibitorsJ Luo, S Wu, H Rizvi, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|April 28, 2016
Systematic evaluation of pembrolizumab dosing in patients with advanced non-small-cell lung cancerM Chatterjee, D C Turner, E Felip, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|August 23, 2019
Outcomes to first-line pembrolizumab in patients with non-small-cell lung cancer and very high PD-L1 expressionE J Aguilar, B Ricciuti, J F Gainor, et al.
Pageof 3

Showing results (11-20 of 30) with videos related to

Sort By:
Pageof 3
European Journal of Cancer (Oxford, England : 1990)|April 5, 2016
Characterisation and management of dermatologic adverse events to agents targeting the PD-1 receptorV R Belum, B Benhuri, M A Postow, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|December 22, 2016
Antibody-mediated thyroid dysfunction during T-cell checkpoint blockade in patients with non-small-cell lung cancerJ C Osorio, A Ni, J E Chaft, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|April 5, 2018
Negative association of antibiotics on clinical activity of immune checkpoint inhibitors in patients with advanced renal cell and non-small-cell lung cancerL Derosa, M D Hellmann, M Spaziano, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|April 9, 2016
Clinical outcomes with pemetrexed-based systemic therapies in RET-rearranged lung cancersA Drilon, I Bergagnini, L Delasos, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|February 8, 2017
Pembrolizumab as first-line therapy for patients with PD-L1-positive advanced non-small cell lung cancer: a phase 1 trialR Hui, E B Garon, J W Goldman, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|September 6, 2021
Clinical definition of acquired resistance to immunotherapy in patients with metastatic non-small-cell lung cancerA J Schoenfeld, S J Antonia, M M Awad, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|March 18, 2020
Clinical and molecular correlates of PD-L1 expression in patients with lung adenocarcinomasA J Schoenfeld, H Rizvi, C Bandlamudi, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|May 9, 2022
Deciphering radiological stable disease to immune checkpoint inhibitorsJ Luo, S Wu, H Rizvi, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|April 28, 2016
Systematic evaluation of pembrolizumab dosing in patients with advanced non-small-cell lung cancerM Chatterjee, D C Turner, E Felip, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|August 23, 2019
Outcomes to first-line pembrolizumab in patients with non-small-cell lung cancer and very high PD-L1 expressionE J Aguilar, B Ricciuti, J F Gainor, et al.
Pageof 3